TerminatedNot Applicable

Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer

Stopped: Poor enrollment

United States48 participantsStarted 1996-07

Plain-language summary

RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying the effectiveness of donor peripheral blood stem cell transplant in treating patients with hematologic cancer.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Diagnosis of one of the following: * Chronic myelogenous leukemia * Philadelphia chromosome-positive OR * Molecular evidence of bcr/abl gene rearrangement * Acute myeloid leukemia, acute lymphocytic leukemia, lymphoma, histiocytoses, myelodysplasia, juvenile chronic myelomonocytic leukemia, aplastic anemia, paroxysmal nocturnal hemoglobinuria, or Fanconi's anemia * Confirmed by cytochemistry, immunophenotyping, and/or chromosomal abnormalities * Multiple myeloma * Hereditary immunodeficiency disorders * Confirmed by immunologic determination * Sickle cell anemia or beta-thalassemia * Confirmed by hemoglobin electrophoresis * Storage disorders (e.g., Gaucher's disease, Hurler's disease, or metachromatic leukodystrophy) * Confirmed by metabolic testing * Other non-malignant conditions * Eligible for allogeneic peripheral blood stem cell or bone marrow transplantation PATIENT CHARACTERISTICS: Age: * 65 and under Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Not specified Renal: * Not specified PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * Not specified Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * Not specified

What they're measuring

Toxicity

Timeframe: 6 months

Time to engraftment

Timeframe: 6 months

Trial details

NCT IDNCT00008216

SponsorColumbia University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2009-01